BBI 5000
Alternative Names: BBI-5000Latest Information Update: 14 Sep 2022
Price :
$50 *
At a glance
- Originator Unknown
- Developer Fresh Tracks Therapeutics
- Class Skin disorder therapies
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
- 01 Jul 2019 Discontinued - Phase-I for Atopic dermatitis (In volunteers) in USA (PO) (Brickell Biotech pipeline, July 2019)